Pulmonary nocardiosis in Western Europe-Clinical evaluation of 43 patients and population-based estimates of hospitalization rates.


Journal

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 18 07 2018
revised: 12 12 2018
accepted: 21 12 2018
pubmed: 19 1 2019
medline: 14 6 2019
entrez: 19 1 2019
Statut: ppublish

Résumé

Pulmonary nocardiosis (PN) is an uncommon but potentially life-threatening infection. Most of our knowledge on PN is derived from case reports and small case series. Increasing incidence rates of PN have been reported recently. The aim of this study was to describe the clinical course of and risk factors for PN in four Western European countries and to estimate population-based annual hospitalization rates. This was a retrospective evaluation (1995-2011) of the clinical course of and risk factors for PN in patients at 11 hospitals in four European countries (Germany, Austria, Switzerland, and the Netherlands). Population-based estimates of hospitalization rates for PN in Germany (2005 to 2011) were calculated using official German nationwide diagnosis-related groups (DRG) hospital statistics. Forty-three patients fulfilled stringent criteria for proven (n=8) and probable (n=35) PN; seven had extrapulmonary dissemination. For these 43 patients, the major risk factors for PN were immunocompromising (83.7%) and/or pulmonary (58.1%; as only comorbidity in 27.9%) comorbidities. The median duration of PN targeted therapy was 12 weeks. Distinctive patterns of resistance were observed (imipenem susceptibility: Nocardia farcinica 33.3%; Nocardia asteroides 66.7%). The overall mortality rate was 18.9% (50% in disseminated PN). Over time, annual PN hospitalization rates remained unchanged at around 0.04/100000, with the highest rate among men aged 75-84 years (0.24/100000). PN is a rare, but potentially life-threatening disease, and mainly affects immunocompromised elderly males. Overall, annual hospitalization rates remained stable between 2005 and 2011.

Sections du résumé

BACKGROUND BACKGROUND
Pulmonary nocardiosis (PN) is an uncommon but potentially life-threatening infection. Most of our knowledge on PN is derived from case reports and small case series. Increasing incidence rates of PN have been reported recently. The aim of this study was to describe the clinical course of and risk factors for PN in four Western European countries and to estimate population-based annual hospitalization rates.
METHODS METHODS
This was a retrospective evaluation (1995-2011) of the clinical course of and risk factors for PN in patients at 11 hospitals in four European countries (Germany, Austria, Switzerland, and the Netherlands). Population-based estimates of hospitalization rates for PN in Germany (2005 to 2011) were calculated using official German nationwide diagnosis-related groups (DRG) hospital statistics.
RESULTS RESULTS
Forty-three patients fulfilled stringent criteria for proven (n=8) and probable (n=35) PN; seven had extrapulmonary dissemination. For these 43 patients, the major risk factors for PN were immunocompromising (83.7%) and/or pulmonary (58.1%; as only comorbidity in 27.9%) comorbidities. The median duration of PN targeted therapy was 12 weeks. Distinctive patterns of resistance were observed (imipenem susceptibility: Nocardia farcinica 33.3%; Nocardia asteroides 66.7%). The overall mortality rate was 18.9% (50% in disseminated PN). Over time, annual PN hospitalization rates remained unchanged at around 0.04/100000, with the highest rate among men aged 75-84 years (0.24/100000).
CONCLUSIONS CONCLUSIONS
PN is a rare, but potentially life-threatening disease, and mainly affects immunocompromised elderly males. Overall, annual hospitalization rates remained stable between 2005 and 2011.

Identifiants

pubmed: 30658169
pii: S1201-9712(19)30001-3
doi: 10.1016/j.ijid.2018.12.010
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

140-148

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Sebastian R Ott (SR)

Department of Pulmonary Medicine, University Hospital (Inselspital) and University of Bern, Bern, Switzerland; Department of Pulmonary Medicine and Thoracic Surgery, St. Claraspital, Basel, Switzerland.

N Meier (N)

Department of Pulmonary Medicine, University Hospital (Inselspital) and University of Bern, Bern, Switzerland; Department of Pulmonary Medicine and Thoracic Surgery, St. Claraspital, Basel, Switzerland.

Martin Kolditz (M)

Division of Pulmonology, Medical Department 1, University Hospital of TU Dresden, Dresden, Germany.

Torsten T Bauer (TT)

Department of Pneumology, Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Germany. Electronic address: torsten.bauer@helios-gesundheit.de.

Gernot Rohde (G)

Department of Pneumology and Allergology, Goethe University, Frankfurt, Germany.

Elisabeth Presterl (E)

Klinisches Institut für Krankenhaushygiene, University of Vienna, Vienna, Austria.

Dirk Schürmann (D)

Department of Internal Medicine/Infectious Diseases and Pulmonary Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Philipp M Lepper (PM)

Department of Internal Medicine V, University Hospital of Saarland, Homburg, Germany.

Felix C Ringshausen (FC)

Department of Respiratory Medicine, Hannover Medical School, Hannover, and German Centre for Lung Research (DZL), Hannover, Germany.

Holger Flick (H)

Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

Stephen L Leib (SL)

Institute for Infectious Diseases, University of Bern, Bern, Switzerland.

Mathias W Pletz (MW)

Centre for Infectious Diseases and Infection Control, Jena University Hospital, Jena, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH